Drug Profile
Trastuzumab biosimilar - United BioPharma
Alternative Names: UB 921Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator United BioPharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in Taiwan (IV, Infusion)
- 25 Sep 2017 Phase-I clinical trials in Breast cancer (In volunteers) in Taiwan (IV) (NCT03013881)
- 02 Jan 2017 United BioPharma, in collaboration with Tri-Service General Hospital, plans a phase I trial in Breast Cancer (In volunteers) in Taiwan in June 2017 (NCT03013881)